Cytosorbents Corp (CTSO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CytoSorbents Corporation on September 8, 2026. The report details the effective implementation of a reverse stock split of the Company's common stock, which was approved by shareholders at the 2026 Annual Meeting held on August 13, 2026.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a corporate action regarding capital structure.
Material Changes
- Reverse Stock Split: A one-for-twenty (1:20) reverse stock split became effective at 12:01 a.m. E.T. on September 8, 2026.
- Share Count Reduction: The number of outstanding shares was reduced from 63,022,020 prior to the split. Fractional shares were rounded up to the nearest whole share.
- Capital Structure Adjustments: Outstanding options and warrants were automatically adjusted with a corresponding increase in exercise prices to maintain economic parity.
- Trading Details: Trading on the Nasdaq Capital Market resumed on a split-adjusted basis with a new CUSIP number: 23283X305.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the description of the Certificate of Amendment is qualified by reference to the full text filed as Exhibit 3.1. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the new CUSIP number (23283X305) for accurate trading and settlement.
- Confirm the adjusted number of shares held in brokerage accounts following the 1:20 ratio.
- Review the adjusted exercise prices for any outstanding options or warrants held.
- Check the Company's subsequent filings for any impact on Nasdaq listing compliance.